Salicylamide

Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent. In Vitro: Treatment with salicylamides leads to the bacterial growth inhibition which correlates with the level of inhibition of sulfate reduction^[1]. In Vivo: Salicylamide administration decreases the levels of radiosulfate in maternal serum and placenta, and impaires the incorporation of radiosulfate into fetal skeletal GAGs. Salicylamide administration results in a decrease in the calcium content of fetal limb bones, but has no significant effect on maternal serum calcium^[2]. Salicylamide administration decreases radiosulfate uptake by maternal serum and liver, fetus and placenta--effects being dose-dependent. Differences in radiosulfate uptake by the fetus and placenta over time, induced by salicylamide, are also significant independently of maternal serum levels of radiosulfate^[3].